 The shares of Supernus Pharmaceuticals Inc NASDAQ:SUPN are up 17.7 at 26.50 at last check, after its experimental drug for attention deficit hyperactivity disorder ADHD, SPN-812, met its main goal in a late-stage study in adults. 